World neurosurgery · 2025
Evaluation of Neuroendoscopy-Assisted Surgery for the Treatment of the Trabecular Subtype of Chronic Subdural Hematoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hong Jingyang, Shan Zundao, Li Jinjian, Zhu Yinxin, Chen Keng, Niu Huanjiang, Wang Yirong, Wang Kun
Аннотация
OBJECTIVE: This retrospective study compared the outcomes of neuroendoscopy-assisted small craniotomy (n = 26) and traditional burr hole drainage (n = 20) for the treatment of trabecular chronic subdural hematoma (CSDH).
METHODS: The 2 groups showed comparable baseline characteristics including age, sex, comorbidities, and medication use (all, P > 0.05).
RESULTS: The neuroendoscopy group demonstrated several clinical advantages despite longer operative times (108.7 ± 45.2 vs. 92.5 ± 45.8 minutes, P < 0.05). Most notably, significantly lower recurrence (3.8% vs. 30%, P < 0.05) and postoperative seizure rates (3.8% vs. 25%, P < 0.05) were observed during the 6-month follow-up period. Both surgical approaches showed similar hospital stays (11.7 ± 3.2 vs. 10.2 ± 2.8 days) and rebleeding rates (3.8% vs. 15%). Functional recovery measures revealed better outcomes with neuroendoscopy, as evidenced by superior Modified Rankin Scale scores (1.1 ± 0.3 vs. 1.5 ± 1.0, P < 0.05). Both techniques resulted in significant postoperative improvements in Barthel Index scores (P < 0.05). Importantly, neither group experienced major complications such as cerebral infarction or surgical site infections.
CONCLUSIONS: These findings suggest that neuroendoscopy-assisted surgery offers distinct advantages for trabecular CSDH management, particularly in reducing the recurrence risk and enhancing functional recovery. This technique appears safe and may represent a superior surgical option for this specific CSDH subtype.
METHODS: The 2 groups showed comparable baseline characteristics including age, sex, comorbidities, and medication use (all, P > 0.05).
RESULTS: The neuroendoscopy group demonstrated several clinical advantages despite longer operative times (108.7 ± 45.2 vs. 92.5 ± 45.8 minutes, P < 0.05). Most notably, significantly lower recurrence (3.8% vs. 30%, P < 0.05) and postoperative seizure rates (3.8% vs. 25%, P < 0.05) were observed during the 6-month follow-up period. Both surgical approaches showed similar hospital stays (11.7 ± 3.2 vs. 10.2 ± 2.8 days) and rebleeding rates (3.8% vs. 15%). Functional recovery measures revealed better outcomes with neuroendoscopy, as evidenced by superior Modified Rankin Scale scores (1.1 ± 0.3 vs. 1.5 ± 1.0, P < 0.05). Both techniques resulted in significant postoperative improvements in Barthel Index scores (P < 0.05). Importantly, neither group experienced major complications such as cerebral infarction or surgical site infections.
CONCLUSIONS: These findings suggest that neuroendoscopy-assisted surgery offers distinct advantages for trabecular CSDH management, particularly in reducing the recurrence risk and enhancing functional recovery. This technique appears safe and may represent a superior surgical option for this specific CSDH subtype.